Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYou do not need to wean off Wegovy in the way you would taper a steroid or antidepressant. Semaglutide has no pharmacological dependency, so there is no clinical requirement to reduce the dose gradually before stopping. That said, stopping without a plan — and without speaking to your prescriber first — carries real practical consequences for most people. Wegovy is a prescription-only medicine, and any decision to stop or adjust it should be made with the clinician who oversees your treatment, not based on a forum thread or a hunch.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide works by activating GLP-1 receptors in the brain and gut, which damps appetite signals and slows how quickly food leaves the stomach. While you are taking it, those effects are sustained. Once the last dose clears your system (semaglutide's half-life is around a week, so it takes roughly five weeks to wash out fully) those receptor effects fade with it.
What follows is not withdrawal in any clinical sense. There is no rebound anxiety, no physical craving for the medicine itself. What does return, for most people, is hunger. Not dramatically, not overnight, but steadily. Trial data from the STEP 1 study, published in the New England Journal of Medicine, found that participants who stopped semaglutide after 68 weeks regained roughly two-thirds of the weight they had lost within the following year. That is not a taper problem. It reflects the fact that the underlying biology driving weight gain has not changed; the medicine was managing it.
Knowing this before you stop is more useful than any dose-reduction schedule. If you are asking whether you actually need to taper off Wegovy, the answer depends far more on your individual circumstances and what happens next than on any standard weaning schedule.
The NHS England guidance on weight-management injections is clear that stopping treatment is a clinical decision, not a logistical one. Your prescriber will want to know why you are considering stopping (whether that is side effects, cost, pregnancy plans, surgery, or simply feeling you have reached your goal) because each reason leads to a different recommendation.
If side effects are the driver, a dose reduction (rather than stopping entirely) is often worth trying first. If you are planning surgery, your team needs advance notice because anaesthetists need to know about GLP-1 medicines before any procedure. If you are trying to conceive, there is a washout period to factor in. None of these conversations should happen after you have already given yourself the last pen.
One practical habit worth building now: check your remaining supply at the start of each week, rather than when you open the last pen. That 30-second check gives you enough lead time to have the stopping conversation before the decision is made for you by an empty box.
For people on higher doses who want to stop by choice rather than necessity, some prescribers do suggest stepping back down through the dose schedule before stopping. This is not because the medicine requires it physiologically, but because it can reduce the abruptness of appetite returning and make the transition more manageable day-to-day. There is no formal protocol for this in the UK SmPC, so any taper plan is a clinical judgement call, which is precisely why it belongs in a conversation, not a self-help article.
If you are wondering about the best way to wean off Wegovy for your specific situation, the honest answer is that there is no single right method. It depends on your current dose, your reasons for stopping, your weight history, and what comes next. Our page on how to wean off Wegovy walks through the practical steps in more detail, though any plan should still be reviewed with a prescriber who knows your case before you act on it.
For context on the broader question of whether stopping is even the right call, our page on whether you should wean off Wegovy looks at the evidence on long-term treatment versus stopping, which may reframe the decision entirely.
Stopping Wegovy does not mean abandoning progress. Lifestyle changes made during treatment (eating patterns, activity habits, understanding hunger cues) remain available to you. The evidence does show those changes are harder to sustain without the appetite reduction the medicine provides, but they are not erased.
If you stopped and are now reconsidering, or if you are thinking about switching to a different treatment, our Wegovy overview sets out the current UK landscape, including what the medicine is licensed for and how it compares with other options. The semaglutide information page covers the wider picture of how the molecule works across its different licensed uses.
For anyone considering restarting treatment or exploring an alternative, our prescribers review each case individually, including people who have previously stopped. If you want to understand whether you are still a candidate, checking your eligibility costs nothing and takes a few minutes. Each review is carried out by a real prescriber, not automated screening, on the day your consultation arrives.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.